Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Blue Trust Inc.

Blue Trust Inc. lowered its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 61.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,667 shares of the company’s stock after selling 8,952 shares during the quarter. Blue Trust Inc.’s holdings in Teva Pharmaceutical Industries were worth $125,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in TEVA. Creative Planning grew its stake in Teva Pharmaceutical Industries by 4.5% in the third quarter. Creative Planning now owns 42,815 shares of the company’s stock worth $772,000 after purchasing an additional 1,863 shares in the last quarter. Raymond James & Associates grew its position in shares of Teva Pharmaceutical Industries by 25.1% in the 3rd quarter. Raymond James & Associates now owns 1,020,719 shares of the company’s stock worth $18,393,000 after acquiring an additional 204,775 shares in the last quarter. Sequoia Financial Advisors LLC grew its position in shares of Teva Pharmaceutical Industries by 0.7% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock worth $2,025,000 after acquiring an additional 805 shares in the last quarter. Signaturefd LLC grew its position in shares of Teva Pharmaceutical Industries by 16.9% in the 3rd quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock worth $137,000 after acquiring an additional 1,094 shares in the last quarter. Finally, Private Advisor Group LLC boosted its holdings in Teva Pharmaceutical Industries by 12.9% in the third quarter. Private Advisor Group LLC now owns 26,104 shares of the company’s stock worth $470,000 after purchasing an additional 2,990 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on TEVA. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Barclays decreased their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Finally, UBS Group decreased their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $23.57.

Insiders Place Their Bets

In related news, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now owns 695,000 shares of the company’s stock, valued at $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.55% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Trading Down 1.5 %

Teva Pharmaceutical Industries stock opened at $16.75 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The firm has a 50-day moving average price of $19.92 and a two-hundred day moving average price of $18.48. The firm has a market capitalization of $18.97 billion, a price-to-earnings ratio of -11.55, a PEG ratio of 1.39 and a beta of 0.71. Teva Pharmaceutical Industries Limited has a 52-week low of $12.51 and a 52-week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Sell-side analysts expect that Teva Pharmaceutical Industries Limited will post 2.61 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.